Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financi...(upon request from the Company. The Compa...)

                          CATALYST PHARMACEUTICAL PARTNERS, INC.
                             (a development stage company)
                   CONDENSED STATEMENTS OF OPERATIONS (unaudited)

                              For the Three Months    For the Six Months
                                 Ended June 30,          Ended June 30,
                                 --------------          --------------
                             2009           2008       2009           2008
                             ----           ----       ----           ----
    Revenues                     $-             $-           $-          $-

    Operating costs and
     expenses:
       Research and
        development        1,376,253     1,902,144    3,698,885    2,986,503
       General and
        administrative       392,559       561,533    1,114,470    1,201,206
                             -------       -------      -------      -------
         Total operating
          costs and
         expenses          1,768,812     2,463,677    4,813,355    4,187,709
                             -------       -------      -------      -------
       Loss from
        operations        (1,768,812)   (2,463,677)  (4,813,355)  (4,187,709)
    Interest income            6,925        86,237       20,267      226,222
                             -------       -------      -------      -------
       Loss before income
        taxes             (1,761,887)   (2,377,440)  (4,793,088)  (3,961,487)
    Provision for
     income taxes                  -             -          -              -
                             -------       -------      -------      -------
       Net loss          $(1,761,887)  $(2,377,440) $(4,793,088) $(3,961,487)
                    
'/>"/>
SOURCE  Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time